Natural Products as Modulators of CES1 Activity

被引:15
|
作者
Qian, Yuli [1 ]
Markowitz, John S. [1 ]
机构
[1] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA
关键词
DRUG-DRUG INTERACTIONS; ST-JOHNS WORT; CARBOXYLESTERASE; HUMAN PLASMA; LIQUID-CHROMATOGRAPHY; GLYCYRRHETIC ACID; GAMBOGIC ACID; ORANGE JUICE; PHARMACOKINETIC PROFILES; SELECTIVE INHIBITORS;
D O I
10.1124/dmd.120.000065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Carboxylesterase (CES) 1 is the predominant esterase expressed in the human liver and is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate medications (e.g., methylphenidate, clopidogrel, oseltamivir). Therefore, any perturbation of CES1 by coingested xenobiotics could potentially compromise treatment. Natural products are known to alter drug disposition by modulating cytochrome P450 and UDP-glucuronosyltransferase enzymes, but this issue is less thoroughly explored with CES1. We report the results of a systematic literature search and discuss natural products as potential modulators of CES1 activity. The majority of research reports reviewed were in vitro investigations that require further confirmation through clinical study. Cannabis products (Delta(9)-tetrahydrocannabinol, cannabidiol, cannabinol); supplements from various plant sources containing naringenin, quercetin, luteolin, oleanolic acid, and asiatic acid; and certain traditional medicines (danshen and zhizhuwan) appear to pose the highest inhibition potential. In addition, ursolic acid, gambogic acid, and glycyrrhetic acid, if delivered intravenously, may attain high enough systemic concentrations to significantly inhibit CES1. The provision of a translational interpretation of in vitro assessments of natural product actions and interactions is limited by the dearth of basic pharmacokinetic data of the natural compounds exhibiting potent in vitro influences on CES1 activity. This is a major impediment to assigning even potential clinical significance. The modulatory effects on CES1 expression after chronic exposure to natural products warrants further investigation. SIGNIFICANCE STATEMENT Modulation of CES1 activity by natural products may alter the course of treatment and clinical outcome. In this review, we have summarized the natural products that can potentially interact with CES1 substrate medications. We have also noted the limitations of existing reports and outlined challenges and future directions in this field.
引用
收藏
页码:993 / 1007
页数:15
相关论文
共 50 条
  • [31] The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects
    Stage, Claus
    Jurgens, Gesche
    Guski, Louise Schow
    Thomsen, Ragnar
    Bjerre, Ditte
    Ferrero-Miliani, Laura
    Lyauk, Yassine Kamal
    Rasmussen, Henrik Berg
    Dalhoff, Kim
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1506 - 1514
  • [32] Marine natural products as aβ modulators
    Garcia-Palomero, E.
    Usan, P.
    Garcia, P.
    Delgado, E.
    de Austria, C.
    Saiz, G.
    Perez, M. A.
    Sanchez-Quesada, J.
    Dorronsoro, I
    Castro, A.
    Medina, M.
    NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS: ADPD 2009, 2009, : 135 - 139
  • [33] Natural products as angiogenesis modulators
    El Sayed, KA
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 971 - 993
  • [34] Natural Products as Modulators of Sirtuins
    Mayack, Berin Karaman
    Sippl, Wolfgang
    Ntie-Kang, Fidele
    MOLECULES, 2020, 25 (14):
  • [35] Original Rapid bioluminescence assay for monitoring rat CES1 activity and its alteration by traditional Chinese medicines
    Zhang, Jun
    Wang, Dandan
    Zou, Liwei
    Xiao, Min
    Zhang, Yufeng
    Li, Ziwei
    Yang, Ling
    Ge, Guangbo
    Zuo, Zhong
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2020, 10 (03) : 253 - 262
  • [36] Individualised methylphenidate therapy based on pharmacogenomics: focus on carboxylesterase1 (CES1)
    Houmann, Tine
    Skovgaard, Anne Mette
    Rasmussen, Henrik Berg
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2011, 20 (01) : S120 - S120
  • [37] Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny
    Hines, Ronald N.
    Simpson, Pippa M.
    McCarver, D. Gail
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (07) : 959 - 966
  • [38] The correlation of CES1 genotype and minimal plasmatic concentration of dabigatran in stroke patients
    Tomek, A.
    Kesnerova, P.
    Sarbochova, I.
    Magerova, H.
    Paulas-Schwabova, J.
    Ruzickova, T.
    Lacinova, Z.
    Kaplan, V.
    Klima, J.
    Matoska, V.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 269 - 269
  • [39] Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis
    Lian, Jihong
    Bahitham, Wesam
    Panigrahi, Rashmi
    Nelson, Randal
    Li, Lena
    Watts, Russell
    Thiesen, Aducio
    Lemieux, M. Joanne
    Lehner, Richard
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2018, 1863 (07): : 688 - 699
  • [40] The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
    Liu, Yue
    Yang, Chenguang
    Qi, Wenyuan
    Pei, Zuowei
    Xue, Wei
    Zhu, Huolan
    Dong, Min
    Guo, Ying
    Cong, Duanduan
    Wang, Fang
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 477 - 485